Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 vs Topotecan in Recurrent Small Cell Lung Cancer
NCT06500026Phase 3Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of izalontamab brengitecan in small cell lung cancer (SCLC) (2 arms), sponsored by Biokin Pharmaceutical. Primary endpoint: Overall Survival at 24 months. Started Aug 2024; status: active, not recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06500026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06500026.